Sinew Pharma Inc. (6634.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Taiwan · ISIN TW0006634009

Price
53.40 TWD
Market cap
3.81 bn TWD
P/E (2025)
–
P/S (2025)
80,996.36
Dividend yield
0.00 %
Net margin
-263,287.23 %
Return on equity (ROE)
-11.34 %
Return on assets (ROA)
-10.97 %

Sinew Pharma Inc. financials

Fiscal year20242025
Revenue0.00 TWD47,000.00 TWD
Gross profit-30.31 m TWD37,000.00 TWD
Operating income-168.86 m TWD-140.13 m TWD
EBIT-149.96 m TWD-123.09 m TWD
Net income-150.37 m TWD-123.75 m TWD
Diluted EPS – continuing operations-2.11 TWD-1.74 TWD

Full history since 2019, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Sinew Pharma Inc.

Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan. It is also developing SNP-810 is in phase II clinical trial for use in pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States. Sinew Pharma Inc. was founded in 2014 and is based in Taipei City, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.